⏳ Fetching live dividend data...
Home › Calculator › PHRRF Dividend Calculator 2026
PharmaTher Holdings Ltd. · OTC
Price: $0.04 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in PHRRF → $1133618439221047.25M in 10 years · $92,606,806,458,602,680,000.00/month
PharmaTher Holdings Ltd. is a biotechnology firm in the clinical stage, specializing in psychedelic treatments. Its primary objective is to investigate, develop, and bring to market innovative applications, drug forms, and administration techniques for psychedelics, addressing conditions such as mental health issues, neurological diseases, and chronic pain. Among its pipeline of products, the company is advancing an intravenous ketamine injection, which is currently undergoing Phase II and III clinical trials for its potential use in treating Parkinson's disease, providing anesthesia and sedation, and managing amyotrophic lateral sclerosis (ALS). Additionally, PharmaTher is developing a Ketamine Patch, in Phase I and II trials for conditions like depression, various mental health disorders, complex regional pain syndrome (CRPS), and other pain-related ailments. A Ketamine Pump is also part of their development, currently in Phase II clinical trials for applications in mental health, pain management, and surgical/procedural settings. Furthermore, the company is actively working on PHARMAPATCH, a microneedle patch designed for the transdermal delivery of psychedelic compounds. PharmaTher has established several strategic partnerships to further its development. These include collaborations with LTS Lohmann Therapie-Systeme AG for a ketamine microneedle patch, Alcami Corporation for ketamine injectables and infusions, and BioRAE, Inc. for ketamine pump development. They are also working with Revive Therapeutics Ltd. on a psilocybin microneedle patch and with Gesval S.A. on a patented continuous-flow process for producing ketamine and its analogs. The company is also developing its own proprietary wearable ketamine delivery system, specifically tailored for mental health, neurological, and pain disorders. Established in 2019, the company maintains its headquarters in Toronto, Canada.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open PHRRF position with:
Real after-tax yield depends on where you live and how you hold PHRRF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 4975.12% | 4972.32% | $497,512 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 4228.85% | 4226.05% | $422,885 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 3980.10% | 3977.30% | $398,010 / yr |
| 🇬🇧 UK ISA | 0% | 4975.12% | 4972.32% | $497,512 / yr |
| 🇬🇧 UK Taxable | 8.75% | 4539.80% | 4537.00% | $453,980 / yr |
| 🇨🇦 TFSA | 0% | 4975.12% | 4972.32% | $497,512 / yr |
| 🇨🇦 CA Taxable | 25% | 3731.34% | 3728.54% | $373,134 / yr |
| 🇦🇺 Super (pension) | 15% | 4228.85% | 4226.05% | $422,885 / yr |
| 🇦🇺 AU Taxable | 30% | 3482.58% | 3479.78% | $348,258 / yr |
| 🇩🇪 DE Taxable | 26.375% | 3662.93% | 3660.13% | $366,293 / yr |
| 🇫🇷 FR Taxable | 30% | 3482.58% | 3479.78% | $348,258 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
PHRRF pays quarterly — 4 times per year. Next ex-div: TBD.
How PHRRF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for PHRRF sourced from FMP /financial-growth endpoint — real data, not estimates.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the PHRRF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →